Medical Education

Delve into the latest in medical education resources for NASH. Explore new studies, teaching methodologies, and advancements shaping NASH education for healthcare professionals.

Surveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives

Authors: Younossi ZM et al.
Published in Journal of Hepatology (November 2023)
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase with the rise of type 2 diabetes and obesity.
Read MoreSurveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives

Advancing Fibrosis Imaging: An Evaluation of Radiotracer Efficacy

Authors: Eriksson O and Velikyan I
Published in Pharmaceuticals (November 2023)
Tissue fibrosis is induced by an excessive collagen deposition in organs suffering from inflammation and is associated with several diseases, including non-alcoholic steatohepatitis (NASH).
Read MoreAdvancing Fibrosis Imaging: An Evaluation of Radiotracer Efficacy

Machine Learning Models for the Detection of (At-Risk) NASH: Unravelling the Potential

Authors: Lee J, Westphal M, Vali Y et al.
Published in Hepatology (July 2023)
Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of non-alcoholic steatohepatitis (NASH).
Read MoreMachine Learning Models for the Detection of (At-Risk) NASH: Unravelling the Potential

Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?

Authors: Csermely A, Mantovani A, Morieri ML et al.
Published in Diabetes & Metabolism (September 2023)
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), affects 30% of adults worldwide and up to 40% of those with type 1 diabetes mellitus (T1DM)
Read MoreMultiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?

Research Priorities in NAFLD: Ensuring Personalised and Multidisciplinary Patient Care

Authors: Iruzubieta P, Bataller R, Arias-Loste MT et al.
Published in Clinics in Liver Disease (May 2023)
Both non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), NAFLD’s inflammatory and progressive subtype, are the histologic manifestations of a heterogeneous disease intricately linked with metabolic disorders.
Read MoreResearch Priorities in NAFLD: Ensuring Personalised and Multidisciplinary Patient Care

Managing Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum

Authors: Pais R, Cariou B, Noureddin M et al.
Published in Journal of Hepatology (September 2023)
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Read MoreManaging Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum

Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

Authors: Fromenty B, Roden M
Published in Journal of Hepatology (February 2023)
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
Read MoreExamining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

Authors: Loomba R, Huang DQ, Sanyal AJ et al.
Published in Gut (March 2023)
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
Read MoreNASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

NAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

Authors: Younossi ZM, Golabi P, Paik JM et al.
Published in Hepatology (April 2023)
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection with obesity, a significant public health issue showing increasing prevalence rates globally and regionally, necessitates comprehensive education focused on NAFLD and the implementation of worldwide policies to address it effectively.
Read MoreNAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

NAFLD and New-Onset Heart Failure: What is the Link?

Authors: Inciardi RM, Mantovani A and Targher G
Published in Current Heart Failure Reports (July 2023)
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Read MoreNAFLD and New-Onset Heart Failure: What is the Link?

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES